Annovis Bio Announces Public Offering to Fund Alzheimer's Trial

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, has announced a proposed underwritten public offering of common stock and accompanying warrants. The company, headquartered in Malvern, Pennsylvania, is focused on advancing its lead drug candidate, buntanetap, which targets the underlying causes of Alzheimer's disease (AD) and Parkinson's disease (PD). Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing these root causes, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The net proceeds from the offering will support continued clinical development of buntanetap in a Phase 3 Alzheimer’s disease study, as well as for working capital and general corporate purposes.

This news highlights Annovis Bio's commitment to combating neurodegenerative diseases, which affect millions worldwide. The company's approach is unique in that it targets multiple toxic proteins simultaneously, potentially offering a more comprehensive treatment compared to existing therapies that focus on single targets. The proposed public offering is a strategic move to secure the necessary funding for the late-stage clinical trials that are critical for regulatory approval. For investors, this development signals Annovis's progress and need for capital, which could impact the stock's short-term volatility but also its long-term potential if buntanetap proves successful in trials. The full press release is available at https://ibn.fm/1cxGA.

BioMedWire ("BMW"), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, disseminated this news. BMW focuses on the latest developments in the Biotech, BioMed, and Life Sciences sectors, providing services such as press release distribution, editorial syndication to 5,000+ outlets, and social media distribution. This partnership ensures that Annovis's updates reach a wide audience of investors and industry stakeholders. The company's newsroom is accessible at https://ibn.fm/ANVS for the latest updates on ANVS.